CN111479577A - 用于增强癌症放疗的组合物和方法 - Google Patents
用于增强癌症放疗的组合物和方法 Download PDFInfo
- Publication number
- CN111479577A CN111479577A CN201880047692.1A CN201880047692A CN111479577A CN 111479577 A CN111479577 A CN 111479577A CN 201880047692 A CN201880047692 A CN 201880047692A CN 111479577 A CN111479577 A CN 111479577A
- Authority
- CN
- China
- Prior art keywords
- nutritional supplement
- supplement
- radiation therapy
- tumor
- selenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 266
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 182
- 238000000034 method Methods 0.000 title claims description 72
- 201000011510 cancer Diseases 0.000 title claims description 43
- 230000002708 enhancing effect Effects 0.000 title claims description 12
- 239000000203 mixture Substances 0.000 title abstract description 14
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 213
- 235000021323 fish oil Nutrition 0.000 claims abstract description 135
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 134
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 134
- 239000011669 selenium Substances 0.000 claims abstract description 134
- 239000013589 supplement Substances 0.000 claims abstract description 129
- 230000014509 gene expression Effects 0.000 claims abstract description 90
- 230000000694 effects Effects 0.000 claims abstract description 55
- 230000002195 synergetic effect Effects 0.000 claims abstract description 34
- 206010027476 Metastases Diseases 0.000 claims abstract description 26
- 230000009401 metastasis Effects 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims description 90
- 241001465754 Metazoa Species 0.000 claims description 28
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 25
- 230000000977 initiatory effect Effects 0.000 claims description 22
- 230000001394 metastastic effect Effects 0.000 claims description 17
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 14
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 14
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 14
- 210000000130 stem cell Anatomy 0.000 claims description 12
- 230000033115 angiogenesis Effects 0.000 claims description 5
- 230000001640 apoptogenic effect Effects 0.000 claims description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 3
- 230000002491 angiogenic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- 238000011123 anti-EGFR therapy Methods 0.000 claims 5
- 238000011398 antitumor immunotherapy Methods 0.000 claims 4
- 238000009169 immunotherapy Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 97
- 238000002513 implantation Methods 0.000 abstract description 49
- 238000011262 co‐therapy Methods 0.000 abstract description 20
- 238000002560 therapeutic procedure Methods 0.000 abstract description 16
- 230000009467 reduction Effects 0.000 abstract description 12
- 230000006907 apoptotic process Effects 0.000 abstract description 10
- 230000004580 weight loss Effects 0.000 abstract description 9
- 238000010171 animal model Methods 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 235000019629 palatability Nutrition 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 37
- 230000001225 therapeutic effect Effects 0.000 description 32
- 238000002347 injection Methods 0.000 description 30
- 239000007924 injection Substances 0.000 description 30
- 210000004072 lung Anatomy 0.000 description 28
- 238000011284 combination treatment Methods 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- 230000009469 supplementation Effects 0.000 description 21
- 238000010186 staining Methods 0.000 description 15
- 108090000397 Caspase 3 Proteins 0.000 description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 102000003952 Caspase 3 Human genes 0.000 description 13
- 238000009097 single-agent therapy Methods 0.000 description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 208000016261 weight loss Diseases 0.000 description 8
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000011269 treatment regimen Methods 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 6
- 102000007562 Serum Albumin Human genes 0.000 description 6
- 108010071390 Serum Albumin Proteins 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108700041737 bcl-2 Genes Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000004235 neutropenia Diseases 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 101150024147 bax gene Proteins 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 238000011278 co-treatment Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 235000003715 nutritional status Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 101100162339 Anguilla japonica l-1 gene Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- -1 as in table 1) Chemical compound 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000000339 effect on hypoxia Effects 0.000 description 1
- 230000000212 effect on lymphocytes Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762519087P | 2017-06-13 | 2017-06-13 | |
US62/519,087 | 2017-06-13 | ||
PCT/US2018/037263 WO2018231937A2 (en) | 2017-06-13 | 2018-06-13 | Compositions and methods for enhancing cancer radiotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111479577A true CN111479577A (zh) | 2020-07-31 |
Family
ID=64658660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880047692.1A Pending CN111479577A (zh) | 2017-06-13 | 2018-06-13 | 用于增强癌症放疗的组合物和方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10905723B2 (ja) |
EP (1) | EP3638269A4 (ja) |
JP (2) | JP7336993B2 (ja) |
KR (1) | KR20200078467A (ja) |
CN (1) | CN111479577A (ja) |
CA (1) | CA3066749A1 (ja) |
IL (1) | IL271326A (ja) |
TW (1) | TWI805589B (ja) |
WO (1) | WO2018231937A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115989872A (zh) * | 2022-12-07 | 2023-04-21 | 山东欣希安药业股份有限公司 | 一种改善肿瘤患者营养状态的组合物及其制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7123945B2 (ja) | 2016-10-03 | 2022-08-23 | シャー,ホウン・サイモン | がん放射線療法を増強するための組成物および方法 |
US12029765B2 (en) | 2017-06-13 | 2024-07-09 | Houn Simon Hsia | Compositions and methods for treating cancer |
KR20200078468A (ko) | 2017-06-13 | 2020-07-01 | 호운 사이먼 샤 | 온열 요법을 강화시키기 위한 조성물 및 방법 |
US10905725B2 (en) | 2017-06-13 | 2021-02-02 | Houn Simon Hsia | Compositions and methods for enhancing cancer chemotherapy |
CA3066749A1 (en) | 2017-06-13 | 2018-12-20 | Houn Simon Hsia | Compositions and methods for enhancing cancer radiotherapy |
WO2020205885A1 (en) * | 2019-04-01 | 2020-10-08 | Houn Simon Hsia | Compositions and methods for cancer immunotherapy |
IT202100003899A1 (it) * | 2021-02-19 | 2021-05-19 | Genes S R L | Integratore alimentare per il trattamento nutri-cosmetico dell'alopecia e la prevenzione cardiovascolare |
CN115845056A (zh) * | 2022-07-22 | 2023-03-28 | 山东大学齐鲁医院 | DHA通过抑制心肌细胞中p38/ET-1通路在防治放射性心肌纤维化中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW425285B (en) * | 1996-06-10 | 2001-03-11 | Viva America Marketing Inc | Fish oil and garlic nutritive supplement |
US20140294795A1 (en) * | 2013-03-28 | 2014-10-02 | Houn Simon Hsia | Nutritional Composition |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348483A (en) * | 1981-01-23 | 1982-09-07 | Universal Foods Corporation | Method for the production of chromium yeast |
US4569836A (en) | 1981-08-27 | 1986-02-11 | Gordon Robert T | Cancer treatment by intracellular hyperthermia |
JPS59181159A (ja) | 1983-03-30 | 1984-10-15 | 日東電工株式会社 | 布製外科用絆 |
CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
NZ248605A (en) * | 1993-05-28 | 1994-12-22 | Abbott Lab | Enteral nutritional product comprising protein and fat |
US20020010144A1 (en) | 1994-04-29 | 2002-01-24 | Robert Sobol | Enhancing the sensitivity of tumor cells to therapies |
US5976548A (en) | 1994-11-08 | 1999-11-02 | Viva America Marketing, Inc. | Nutritional supplement composition and use |
US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US6440464B1 (en) | 1996-06-10 | 2002-08-27 | Viva Life Science | Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates |
US6197295B1 (en) | 1996-09-25 | 2001-03-06 | Viva America Marketing Corporation | Dietary supplementation with, and methods for administration of yeast-derived selenium product |
US5810888A (en) | 1997-06-26 | 1998-09-22 | Massachusetts Institute Of Technology | Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery |
AU5334899A (en) | 1998-08-04 | 2000-02-28 | Kosbab, John V. | Nutrient and therapeutic compositions for the treatment of cancer |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
WO2002076548A2 (en) | 2001-03-26 | 2002-10-03 | Ellen, A., Inc. | Methods and apparatus for treating diseased tissue |
US20050013875A1 (en) | 2001-10-25 | 2005-01-20 | Takeshi Kobayashi | Immunopotentiators in thermotherapy for cancer |
EE200400032A (et) | 2002-01-11 | 2004-04-15 | Rath Matthias | Polüfenooliühendit sisaldav farmatseutiline toitekompositsioon ning selle kasutamine vähktõve ravimiseks |
US20040087490A1 (en) | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
AU2002951833A0 (en) | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
US7744930B2 (en) | 2002-11-22 | 2010-06-29 | Shaklee Corporation | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
US8663679B2 (en) | 2004-04-29 | 2014-03-04 | Abbott Laboratories | Compositions for improving breast health in women |
US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
US20070116802A1 (en) * | 2005-11-23 | 2007-05-24 | Carl Germano | High quality caloric composition |
US8017147B2 (en) | 2008-04-07 | 2011-09-13 | Mazed Mohammad A | Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance |
US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
WO2009157759A1 (en) * | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
CN102164595A (zh) | 2008-09-19 | 2011-08-24 | 雀巢产品技术援助有限公司 | 抗癌治疗中的免疫***营养支持 |
US8257694B2 (en) | 2009-05-14 | 2012-09-04 | Product Partners, Llc | Nutritional compositions for reducing oxidative damage |
SG176208A1 (en) | 2009-05-29 | 2012-01-30 | New Chapter Inc | Compositions and methods for modulating lipid composition |
KR101275724B1 (ko) | 2009-12-09 | 2013-06-17 | 한국전자통신연구원 | 단일 기판 집적 회로 장치 및 그 제조 방법 |
US20110189220A1 (en) | 2010-01-29 | 2011-08-04 | New Chapter Inc. | Mushroom compositions and methods for making and using |
WO2011115062A1 (ja) | 2010-03-15 | 2011-09-22 | 国立大学法人 岡山大学 | 抗腫瘍作用補助剤 |
JP2012001479A (ja) | 2010-06-16 | 2012-01-05 | Ishikawa Prefecture | 水溶性ビタミンe含有物より成る生体防御剤 |
US20120010688A1 (en) | 2010-07-09 | 2012-01-12 | Lamb Karl J | Implantable conductive element and method of use inhyperthermic treatment |
US9669053B2 (en) | 2010-07-26 | 2017-06-06 | Chemotherapeutics, Llc | Compositions and methods for enhancing the effectiveness of systemic, HIPEC, IP, and related cancer treatments |
WO2012122295A2 (en) | 2011-03-07 | 2012-09-13 | Ned Biosystems, Inc. | Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin |
WO2014054884A1 (ko) | 2012-10-05 | 2014-04-10 | 연세대학교 산학협력단 | 민감화 물질을 포함하는 온열 치료용 조성물 |
US9072768B2 (en) | 2013-01-22 | 2015-07-07 | Kibow Biotech, Inc. | Composition and method for increasing effectiveness of radiation or chemotherapy |
US9107947B2 (en) | 2013-01-31 | 2015-08-18 | The Penn State Research Foundation | Anti-cancer compositions and methods |
US9889092B2 (en) | 2013-03-13 | 2018-02-13 | The Board Of Regents Of The University Of Texas System | Low density lipoprotein nanocarriers for targeted delivery of omega-3 polyunsaturated fatty acids to cancer |
DE202013002760U1 (de) | 2013-03-21 | 2014-06-23 | Cc Pharma Gmbh | Nahrungsergänzungsmittel zur medikationsorientierten Supplementierung |
JP6495245B2 (ja) | 2013-04-22 | 2019-04-03 | スマートフィッシュ・アーエス | がんの治療及び/又は後治療のための魚油及びジュースを含む組成物の使用 |
CN105705037A (zh) | 2013-07-31 | 2016-06-22 | 株式会社明治 | 用于抑制肿瘤生长的营养组合物 |
CN105658226B (zh) | 2013-08-16 | 2019-05-14 | 港大科桥有限公司 | 使用益生菌治疗癌症的方法和组合物 |
JP6340544B2 (ja) | 2014-02-28 | 2018-06-13 | パナソニックIpマネジメント株式会社 | 食器洗い機 |
US20170246136A1 (en) | 2014-09-24 | 2017-08-31 | OliVentures, Inc. | Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases |
CN105641000A (zh) | 2015-06-01 | 2016-06-08 | 深圳市康道生物有限公司 | 一种含灰树花提取物的抗肿瘤组合物及其制备方法 |
CN105617358A (zh) | 2015-12-29 | 2016-06-01 | 广州市戴菊科技发展有限公司 | 一种具有抗肿瘤功能的医用食品及其制备方法 |
CN105768108A (zh) * | 2016-03-10 | 2016-07-20 | 福格森(武汉)生物科技股份有限公司 | 一种适用于肿瘤患者服用的特膳食品 |
JP6376186B2 (ja) | 2016-08-04 | 2018-08-22 | トヨタ自動車株式会社 | サスペンションメンバ |
JP7123945B2 (ja) | 2016-10-03 | 2022-08-23 | シャー,ホウン・サイモン | がん放射線療法を増強するための組成物および方法 |
CA3066749A1 (en) | 2017-06-13 | 2018-12-20 | Houn Simon Hsia | Compositions and methods for enhancing cancer radiotherapy |
US10905725B2 (en) | 2017-06-13 | 2021-02-02 | Houn Simon Hsia | Compositions and methods for enhancing cancer chemotherapy |
JP2020121479A (ja) | 2019-01-30 | 2020-08-13 | オリンパス株式会社 | 射出成形金型 |
-
2018
- 2018-06-13 CA CA3066749A patent/CA3066749A1/en active Pending
- 2018-06-13 WO PCT/US2018/037263 patent/WO2018231937A2/en unknown
- 2018-06-13 KR KR1020207000858A patent/KR20200078467A/ko not_active Application Discontinuation
- 2018-06-13 JP JP2019569249A patent/JP7336993B2/ja active Active
- 2018-06-13 US US16/007,509 patent/US10905723B2/en active Active
- 2018-06-13 CN CN201880047692.1A patent/CN111479577A/zh active Pending
- 2018-06-13 TW TW107120418A patent/TWI805589B/zh active
- 2018-06-13 EP EP18816771.2A patent/EP3638269A4/en active Pending
-
2019
- 2019-12-11 IL IL271326A patent/IL271326A/en unknown
-
2021
- 2021-01-28 US US17/161,447 patent/US11541079B2/en active Active
-
2023
- 2023-06-07 JP JP2023093880A patent/JP2023105153A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW425285B (en) * | 1996-06-10 | 2001-03-11 | Viva America Marketing Inc | Fish oil and garlic nutritive supplement |
US20140294795A1 (en) * | 2013-03-28 | 2014-10-02 | Houn Simon Hsia | Nutritional Composition |
Non-Patent Citations (2)
Title |
---|
FAHMY , HANAN A.等: "Protective Effects of ω-3 fatty acids and/or Nano-selenium on cisplatin and ionizing radiation induced liver toxicity in rats" * |
HANG WANG等: "Reduction of Splenic Immunosuppressive Cells and Enhancement of Anti-Tumor Immunity by Synergy of Fish Oil and Selenium Yeast" * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115989872A (zh) * | 2022-12-07 | 2023-04-21 | 山东欣希安药业股份有限公司 | 一种改善肿瘤患者营养状态的组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20190054126A1 (en) | 2019-02-21 |
WO2018231937A3 (en) | 2019-03-28 |
WO2018231937A2 (en) | 2018-12-20 |
KR20200078467A (ko) | 2020-07-01 |
JP7336993B2 (ja) | 2023-09-01 |
US10905723B2 (en) | 2021-02-02 |
CA3066749A1 (en) | 2018-12-20 |
TW201902533A (zh) | 2019-01-16 |
TW202342076A (zh) | 2023-11-01 |
JP2023105153A (ja) | 2023-07-28 |
IL271326A (en) | 2020-01-30 |
US20210213071A1 (en) | 2021-07-15 |
EP3638269A2 (en) | 2020-04-22 |
US11541079B2 (en) | 2023-01-03 |
JP2020523374A (ja) | 2020-08-06 |
EP3638269A4 (en) | 2021-03-17 |
TWI805589B (zh) | 2023-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111479577A (zh) | 用于增强癌症放疗的组合物和方法 | |
US20220095667A1 (en) | Compositions and methods for reducing cancer stem cell growth | |
Mauer et al. | Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus | |
US12036246B2 (en) | Compositions and methods for enhancing cancer chemotherapy | |
JP7038432B2 (ja) | 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用 | |
CN107206053A (zh) | 用于治疗血细胞减少症或减少血细胞减少症的持续时间的佛波醇酯组合物和方法 | |
US12029765B2 (en) | Compositions and methods for treating cancer | |
TWI842529B (zh) | 用於增進癌症放射線療效之組合物及方法 | |
CN104027357A (zh) | 一种靶向纳米磁性阿胶及制备方法和应用 | |
Detection | Tag: Becoming Your Own Advocate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40029109 Country of ref document: HK |